The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas.

ABSTRACT: Meningiomas are the most common primary intracranial tumors. The majority of patients can be cured by surgery, or tumor growth can be stabilized by radiation. However, the management of recurrent and more aggressive tumors remains difficult because no established alternative treatment options exist. Therefore, innovative therapeutic approaches are needed. Studies have shown that meningiomas express somatostatin receptors. It is well known from treating neuroendocrine tumors that peptide radioreceptor therapy that targets somatostatin receptors can be effective. As yet, this therapy has been used for treating meningiomas only within individual curative trials. However, small case series and studies have demonstrated stabilization of the disease. Therefore, we see potential for optimizing th

SUBMITTER: Fodi CK 

PROVIDER: S-EPMC9104797 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature